Abstract: Background: The Veterans Health Administration (VA) is committed to consistently addressing high rates of tobacco use among U.S. military veterans. Objective: This study …
Abstract: Objective: To evaluate the effectiveness of behavioural and pharmacological tobacco cessation interventions among active-duty military personnel and veterans. Methods: We …
Abstract: Objective: Social support interventions may enhance access and use of evidence-based tobacco cessation treatments (EBCTs). We assessed the feasibility of a proactive …
Abstract: Introduction: Cigarette smoking remains the leading preventable cause of death in the United States, with prevalence remaining dangerously high in at-risk groups, …
Abstract: INTRODUCTION: Cigarette smoking is a leading cause of preventable death in the United States and disproportionately affects veterans. While smoking cessation is the goal …
Abstract: INTRODUCTION: Certain psychiatric populations have especially low smoking cessation rates. This highlights the need to identify smoking treatments that increase cessation …
Abstract: About 25% of Veterans prescribed opioid analgesics report smoking tobacco. There are reciprocal relationships between tobacco use, chronic pain, and opioid use, including …
Abstract: Tobacco-related deaths remain the leading cause of preventable death in the United States. Veterans suffering from posttraumatic stress disorder (PTSD)-about 11% of those …
Abstract: This analysis was part of the Pain and Smoking Study (PASS), a randomized trial of a cognitive behavioral intervention (CBI) for Veterans with chronic pain who smoke. The …
Abstract: Background: Quitting smoking may lead to improvement in substance use, psychiatric symptoms, and pain, especially among high-risk populations who are more likely to …
Abstract: Introduction: Tobacco use is prevalent and has traditionally been higher in the U.S. Military population than in the civilian population, but studies are limited. The …
Abstract: Background and aims: Smoking is a risk factor for multiple sclerosis (MS) development, symptom burden, decreased medication efficacy, and increased disease-related …